See for yourself:
Our principal medicinal products in the field of diabetes are:
Lantus® (insulin glargine), a long-acting human insulin analog, market leader for branded insulins (IMS source). Lantus® is available is more than 120 countries worldwide (2).
Apidra® (insulin glulisine) a rapid-acting human insulin analog (2).
Insuman®, a range of rapid- and intermediate-acting human insulins (2).
Lyxumia® (lixisenatide) is a once-daily prandial GLP-1 receptor agonist (2).
Amaryl®/Amarel® (glimepiride), a sulfonylurea-class hypoglycemic (2).
Afrezza® (insulin human) is a rapid-acting, inhaled insulin. Only available in the United-States.
Anybody that is long should stay put, anybody that is short should probably cover.
Afrezza is a Blockbuster, and if you don't realize this by now, you probably think the price will not appreciate anytime soon. You may be right, but one day you will be surprised and it will be too late
still confused what he actually blurted out that Matt didn't want us to know.
Sometimes that Matt needs a stiff drink to losen up!
I sure hope they both happen at 5EST on 2/24.
It is not clear on the announcement. If they release the results prior to the conference call, EXPECT a giant bear raid!
LONGS - Honestly you will be caught with your pants down if you do STOP LOSSES!
I for one can not wait for his comments on Afrezza! Maybe he will be asked about this when he takes the helm. Something like.. " Dr Brandicourt, as you are aware Sanofi faces great pressure in it's diabetes portfolio with the patent expiration of Lantus. What are your plans to supplement this? in the past, you worked on a failed product at Pfizer called "Exubera", in your portfolio of diabetic medicine is yet another inhaled inslin product called Afrezza that Sanofi just formed a partnership with. What is the direction you would take this launch? how is it different?"
THAT would be the MONEY question!!
I CHALLENGE EVERY journalist or analyst out there to ask this type of question!!
From a 2007 NYT article......
“Sales have been slower than expected,” said Olivier Brandicourt, general manager for Pfizer’s metabolic and cardiovascular division, which includes Exubera. “It takes time to educate the physician.”
Rochelle Chaiken, Pfizer’s vice president for global medical affairs, said almost 60 percent of diabetes patients had overly high blood sugar levels despite being on standard oral diabetes medications. Many of those patients should be taking Exubera, she said.
But Pfizer’s marketing may not be enough to overcome the medical, economic, practical and legal concerns that have hurt Exubera. In theory, the drug’s biggest advantage over standard injectable insulin is that it is more convenient and does not require needle pricks.
February 10, 2015: 07:00 AM ET
FREDERICK, Md., Feb. 10, 2015 /PRNewswire/ -- Vaccinogen, Inc., (OTC.QB: VGEN) a leading cancer immunotherapy company, announced today that Hakan Edstrom, a healthcare industry veteran with more than 40 years of experience, has been elected to the company's Board of Directors. He will also chair the company's Compensation Committee in this new role and serve on the company's Audit Committee.
"This is an extremely exciting time for Vaccinogen. I'm especially looking forward to helping the company advance the development of the OncoVAX® platform and launch the patient-specific vaccine into its first target market, stage II colon cancer," said Mr. Edstrom. "I believe this truly personalized approach in oncology is the key towards providing better treatment for patients. We've learned over the years that cancer is a highly heterogeneous and personalized disease. I believe Vaccinogen is uniquely positioned to address this need through its tumor-cell vaccine approach which teaches the body to attack its own cancer cells and prevent recurrence of late-stage disease."